Real-world data show no significant differences in overall survival between patients with or without cytogenetic risk factors ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

Bristol Myers Squibb (NYSE:BMY) is paying up to $11.1B in a licensing agreement to help develop BioNTech's (NASDAQ:BNTX) ...

and lung squamous carcinoma cell line (NCI-H226) was provided by Stem Cell Bank, Chinese Academy of Sciences. All these cells were cultured in RPMI 1640 medium (Gibco, USA) supplemented with 10% fetal ...